Immune Activation in HIV-Infected Patients Treated with Different ARV Regimens
| Autor: | Bray Dorothy, Marinella Lauriola, Massimo Coen, Daria Trabattoni, Roberta Terzi, Mario Clerici, Sergio Lo Caputo, Elisabetta Chiesa, Alessia Uglietti, M. Gennaro, Renato Maserati |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Efavirenz business.industry Viremia CD38 medicine.disease Gastroenterology Therapy naive chemistry.chemical_compound chemistry Internal medicine Immunology Medicine Hiv infected patients Protease inhibitor (pharmacology) business CD8 circulatory and respiratory physiology Immune activation |
| Zdroj: | World Journal of AIDS. :97-102 |
| ISSN: | 2160-8822 2160-8814 |
| DOI: | 10.4236/wja.2012.22013 |
| Popis: | Objectives: To evaluate the effects of starting therapy with either Truvada (TVD) or Combivir (CBV) in combination with Efavirenz (EFV) or a boosted Protease Inhibitor (LPV/r, ATV/r, fAPV/r and SQV/r) on clinical, immunological, and virological parameters in HIV-infected antiretroviral (ARV) naive patients. Methods: Twenty-seven patients were prospectively enrolled and received TVD-EFV, 32 TVD-PI/r, 24 CBV-EFV, and 23 CBV-PI/r. Immunovirological analyses were performed at baseline and after 3, 6, 9 and 12 months after initiation of therapy; a full set of data is available for 51 patients. Results: Median CD4+ cell counts and HIV-RNA plasma viremia were comparable in the four groups of patients (TVD-EFV, TVD-PI/r, CBV-EFV, CBV-PI/r) at baseline. At month 12 HIV RNA plasma viremia was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|